Autologous Cell Therapy Market By Therapeutic area, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA
4.1 Overview
4.1.1 Market size and forecast
4.2 Cancer
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.2.4 Cancer Autologous Cell Therapy Market by Type
4.3 Others
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country

CHAPTER 5: AUTOLOGOUS CELL THERAPY MARKET, BY END USER
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospitals
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Cancer treatment centers
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country

CHAPTER 6: AUTOLOGOUS CELL THERAPY MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapeutic area
6.2.3 North America Market size and forecast, by End user
6.2.4 North America Market size and forecast, by country
6.2.4.1 U. S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Therapeutic area
6.2.4.1.3 Market size and forecast, by End user
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Therapeutic area
6.2.4.2.3 Market size and forecast, by End user
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Therapeutic area
6.2.4.3.3 Market size and forecast, by End user
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapeutic area
6.3.3 Europe Market size and forecast, by End user
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Therapeutic area
6.3.4.1.3 Market size and forecast, by End user
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Therapeutic area
6.3.4.2.3 Market size and forecast, by End user
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Therapeutic area
6.3.4.3.3 Market size and forecast, by End user
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Therapeutic area
6.3.4.4.3 Market size and forecast, by End user
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Therapeutic area
6.3.4.5.3 Market size and forecast, by End user
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Therapeutic area
6.3.4.6.3 Market size and forecast, by End user
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapeutic area
6.4.3 Asia-Pacific Market size and forecast, by End user
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Therapeutic area
6.4.4.1.3 Market size and forecast, by End user
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Therapeutic area
6.4.4.2.3 Market size and forecast, by End user
6.4.4.3 India
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Therapeutic area
6.4.4.3.3 Market size and forecast, by End user
6.4.4.4 Australia
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Therapeutic area
6.4.4.4.3 Market size and forecast, by End user
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Therapeutic area
6.4.4.5.3 Market size and forecast, by End user
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Therapeutic area
6.4.4.6.3 Market size and forecast, by End user
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapeutic area
6.5.3 LAMEA Market size and forecast, by End user
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Latin America
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Therapeutic area
6.5.4.1.3 Market size and forecast, by End user
6.5.4.2 Middle East And Africa
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Therapeutic area
6.5.4.2.3 Market size and forecast, by End user

CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Players
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments

CHAPTER 8: COMPANY PROFILES
8.1 Bristol Myers Squibb
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Novartis
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Vericel Corporation
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Gilead Sciences (Kite Pharma, Inc.)
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Johnson & Johnson(Janssen Biotech, Inc)
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Tego Science
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Sanpower Group (Dendreon Pharmaceuticals LLC.)
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Holostem Terapie Avanzate S. r. l.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 GC Biopharma (GC Cell)
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 CORESTEM, Inc
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Autologous Cell Therapy Market,' the autologous cell therapy market was valued at $4.3 billion in 2021, and is estimated to reach $29.1 billion by 2031, growing at a CAGR of 21% from 2022 to 2031.

Autologous cell therapy is an innovative therapeutic intervention in which patient’s own cells are used for treatment. Cells are cultured/engineered, expanded in-vitro, and re-introduced in patient’s body for treatment purpose. Patient specificity, no rejection by the immune system, and least risk of host & graft issues are major advantages of this therapy. Nowadays, cancer is common and a major portion of the population suffers from cancer. The cases of cancer have witnessed a rise, owing to increase in unhealthy lifestyle, aging, tobacco, sun exposure, radiation exposure, and uptake of chemicals in food & beverages. For instance, according to Leukemia and Lymphoma Society, in U.S. around 61,090 people were diagnosed with leukemia in 2021. In addition, around 397,501 people are living with or in remission from leukemia in the U.S. Thus, surge in cancer cases is expected to drive the market growth. Moreover, recent developments in autologous cell therapy has created innovative procedures, which is advancement in minimizing the risk throughout the manufacturing process are the upcoming autologous cell therapy market trends.

The autologous cell therapy such as autologous CAR-T cell therapy in which the T cells are collected from a patient are genetically modified ex vivo and re-injected into the patient. In addition, advantages of autologous therapies include low immunogenicity and the avoidance of graft-versus-host disease.

In addition, other factors that drive growth of global autologous cell therapy market include increase in incidences of neurological disorders (such as multiple sclerosis and Parkinson's disease) and autoimmune disorders. For instance, according to the Multiple Sclerosis Society, in 2019, around 1 million people were living with multiple sclerosis disorder across the globe.

The autologous cell therapy market is driven by rise in incidences of chronic diseases such as autoimmune diseases, cancer, and blood disorders that boost growth of the market. In addition, major players are investing in development and commercialization of autologous cell therapy to decrease incidences of these disorders that fuel the growth of autologous cell therapy industry.

The autologous cell therapy market analysis is segmented into the therapeutic area, end user aand region. Depending on therapeutic area, the autologous cell therapy market size is bifurcated into cancer and others. The cancer segment exhibited highest growth in 2021, and is expected to remain dominant during the autologous cell therapy market forecast period, owing to rise in prevalence of different types cancer across the globe.

On the basis of end user, the autologous cell therapy market size is classified into hospitals and cancer treatment centers. The hospitals segment dominated the autologous cell therapy market share in 2021, owing to well-equipped infrastructure, higher buying power, rise in patient admission, and adoption of technologically advanced autologous cell therapy. In addition, increase in patient’s preference toward hospitals as it safely provides treatment under the observation of skilled physicians. Moreover, the cancer treatment centers segment is projected to register a CAGR of 21.6% during the forecast period owing to rise in number of cancer treatment centers due to surge in prevalence of cancer diseases and availability of a wide range of choice of treatment in some developing nations.

For instance, according to National Cancer Institute (NCI), data published in U.S. 2019, there are 71 INC-Designated Cancer Centers, located in 36 states and the District of Columbia.

Region wise, North America had the highest autologous cell therapy market share in 2021, and is expected to maintain its lead during the forecast period owing to strong presence of key players, availability of approved therapeutics with higher adoption of autologous cell therapy, and huge amount of funding by governments & private firms for clinical trials.

However, Asia-Pacific is expected to witness highest CAGR during the forecast period owing to availability of autologous cell treatments and rise in public awareness of their potential for treating chronic diseases among individuals and healthcare organizations.

Key findings of the study

• By therapeutic area, the cancer segment was highest contributor to the autologous cell therapy industry. in 2021.
• On the basis of end user, the hospitals segment was dominated the market in 2021. However, cancer treatment centers is anticipated to grow at the highest CAGR of 21.6% during the forecast period.
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 22.3% during the forecast period.

Companies Mentioned

• Bristol Myers Squibb
• Novartis
• Vericel Corporation
• Gilead Sciences (Kite Pharma, Inc.)
• Johnson & Johnson(Janssen Biotech, Inc)
• Tego Science
• Sanpower Group (Dendreon Pharmaceuticals LLC.)
• Holostem Terapie Avanzate S.R.L.
• Gc Biopharma (Gc Cell)
• Corestem, Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.